Skip to content
Screener
Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
-$22.86M-68.8%-$8.06M+64.9%-$31.86M-86.8%-$15.45M-34.2%-$13.55M-394%
$136K-2.9%$113K-18.7%$130K-11.6%$139K-12.6%$140K-31.7%
$2.9M+53.7%$2.32M+46.1%$1.38M-42.7%$2.78M+76.1%$1.88M+22.4%
-$9.44M-19.3%-$14.81M+36.7%-$8.47M-30.5%-$12.65M-6.5%-$7.91M-13.0%
$212K+98.1%$52K-61.5%$85K+467%$235K+194%$107K+206%
-$212K-98.1%-$52K+61.5%-$85K-467%-$235K-194%-$107K-206%
$44.99M+749,967%$8K+33.3%-$6K-204%
$4.42M-78.6%$660K+320%$81.41M$0-100%
-$12.24M-50.8%-$10.44M-261%$68.53M-$8.12M
-$9.65M-20.3%-$14.86M+36.9%-$8.55M-31.5%-$12.88M-7.7%-$8.02M-13.9%

FAQ

How much cash does Aquestive Therapeutics, Inc. generate?
Aquestive Therapeutics, Inc. (AQST) generated -$45.4M in operating cash flow over the trailing twelve months.
What is Aquestive Therapeutics, Inc.'s free cash flow?
After $584.0K of capital expenditures, Aquestive Therapeutics, Inc.'s free cash flow was -$45.9M over the trailing twelve months, up 8.1% year over year.
Where does Aquestive Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.